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Abstract
Background: Policy makers, governments and donors are faced with an information gap when considering ways
to improve access to artemisinin-based combination therapy (ACT) and malaria diagnostics including rapid
diagnostic tests (RDTs). To help address some of these gaps, a five-year multi-country research project called
ACTwatch was launched. The project is designed to provide a comprehensive picture of the anti-malarial market to
inform national and international anti-malarial drug policy decision-making.
Methods: The project is being conducted in seven malaria-endemic countries: Benin, Cambodia, the Democratic
Republic of Congo, Madagascar, Nigeria, Uganda and Zambia from 2008 to 2012.
ACTwatch measures which anti-malarials are available, where they are available and at what price and who they
are used by. These indicators are measured over time and across countries through three study components:
outlet surveys, supply chain studies and household surveys. Nationally representative outlet surveys examine the
market share of different anti-malarials passing through public facilities and private retail outlets. Supply chain
research provides a picture of the supply chain serving drug outlets, and measures mark-ups at each supply chain
level. On the demand side, nationally representative household surveys capture treatment seeking patterns and use
of anti-malarial drugs, as well as respondent knowledge of anti-malarials.
Discussion: The research project provides findings on both the demand and supply side determinants of anti-
malarial access. There are four key features of ACTwatch. First is the overlap of the three study components where
nationally representative data are collected over similar periods, using a common sampling approach. A second
feature is the number and diversity of countries that are studied which allows for cross-country comparisons.
Another distinguishing feature is its ability to measure trends over time. Finally, the project aims to disseminate
findings widely for decision-making.
Conclusions: ACTwatch is a unique multi-country research project that threads together anti-malarial supply and
consumer behaviour to provide an evidence base to policy makers that can help determine where interventions
may positively impact access to and use of quality-assured ACT and RDTs. Because of its ability to detect change
over time, it is well suited to monitor the effects of policy or intervention developments in a country.
Background
Artemisinin-based combination therapy (ACT) is recom-
mended by the WHO as the first-line treatment of Plas-
modium falciparum malaria. By 2006, most malaria
endemic countries had changed their national treatment
guidelines to follow these recommendations [1], but
despite increased financing for malaria control over the
last decade [2], the global ta r g e to fa tl e a s t8 0 %o fc h i l -
dren under five with malaria receiving an effective anti-
malarial is far from being met [3]. Today, the use of inef-
fective monotherapies remains widespread [4] and the
development of artemisinin resistance [5] has raised spe-
cific concerns around how to reduce the use of artemisi-
nin monotherapies in order to contain resistance to this
drug that is largely seen as the only effective treatment
option currently available [6].
Many countries are accelerating their efforts to increase
coverage of ACT, with support from funders including
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Malaria, the President’s Malaria Initiative and the World
Bank Booster Programme. In 2010 alone, more than 200
million doses of ACT were forecasted to enter the market
[7]. The most significant recent intervention is the
Affordable Medicines Facility-malaria (AMFm) launched
in 2010 that aims to increase access to high-quality ACT
in the public and private sectors through a novel co-pay-
ment fund worth $216 million in Phase 1 [8]. To date,
orders for over 150 million treatments have been placed
mainly by the private sector in the 9 pilot programmes
operating in eight countries [9].
Despite these and other on-going efforts to increase
access, robust evidence on the availability and use of the
different anti-malarials is sparse. Policy makers, govern-
ments and donors are faced with an information gap when
trying to determine how to improve access to high quality
ACT and reduce the use of artemisinin monotherapies;
and rigorous approaches are needed to evaluate interven-
tions such as the AMFm. [10]. Furthermore, since WHO
issued the recommendation that anti-malarials be
restricted to patients with a confirmed malaria diagnosis
[11], information on the availability of diagnostic services
and tools such as RDTs in the market has become crucial.
To help address some of these gaps, Population Services
International (PSI) in partnership with the London School
of Hygiene and Tropical Medicine (LSHTM) launched a
five-year multi-country research project in 2008 called
ACTwatch. The project aims to provide a comprehensive
picture of the anti-malarial market to inform national and
international policy makers. It is designed to detect
changes in the availability, price and use of anti-malarials
over time and between sectors, and to monitor the effects
of policy or intervention developments at country level.
ACTwatch addresses both the supply and demand sides of
the market. The supply side is evaluated by collecting data
in public and private sector outlets and wholesalers of
anti-malarial drugs. To evaluate demand, data on consu-
mer treatment-seeking behaviour and knowledge are col-
lected at the household level. In combination, the research
components thread together the anti-malarial market and
consumer behaviour to provide this comprehensive over-
view. Findings can help determine where and to what
extent interventions have positively impacted access to
and use of quality-assured ACT and RDTs as well as
inform artemisinin resistance containment efforts.
Methods
An ACTwatch Advisory Committee was established to
help ensure that the project’s methods were rigorous
and its outputs relevant to policy makers. The commit-
tee is made up of 19 leading professionals comprising
academics, researchers, public health implementers,
donors, advocates and members from the private sector.
In addition, consultation was held with the respective
national malaria control programmes and other relevant
bodies. Necessary authorizations including ethical
approval were sought and obtained for each study
country.
Population
The project is being conducted in seven malaria-endemic
countries: Benin, Cambodia, the Democratic Republic of
Congo, Madagascar, Nigeria, Uganda and Zambia between
2008 and 2012 (Figure 1). Countries were selected with
the aim of studying a diverse range of markets from which
comparisons and contrasts could be made considering fac-
tors such as demand for anti-malarials (reflected by
malaria burden), size of the population at risk, pharmaceu-
tical regulation (high/low), nature of pharmaceutical regu-
lation (Francophone versus Anglophone), public sector
capacity and coverage, existence of local anti-malarial
manufacturing, existence of anti-malarial subsidy interven-
tions and the feasibility of receiving necessary country
level authorization to conduct the research.
The research questions and indicators
The research sets out to measure which anti-malarials are
available where and at what price, and who they are used
by. It examines market share of different anti-malarials
passing through public facilities and private retail outlets.
It also provides a picture of the distribution channels
serving these outlets, mapping out the supply chain and
the mark-ups levied across each level. Provider knowledge
and attitudes are also assessed. On the demand side, ACT-
watch measures treatment seeking patterns and use of
anti-malarial drugs, as well as respondent knowledge and
awareness of ACT at the household level. It also explores
factors that influence treatment choices. Further details
can be found in accompanying publications (O’Connell et
al: Got ACTs? Availability, price, market share and provi-
der knowledge of antimalarial medicines in public and pri-
vate sector outlets in six malaria-endemic countries,
submitted) and Littrell et al: Monitoring fever treatment
behavior and equitable access to effective medicines in the
context of initiatives to improve ACT access: baseline
results and implications for programming in six African
countries, submitted).
Three different studies are conducted in each country, as
shown in Figure 2, which together provide a comprehen-
sive understanding of the anti-malarial market: 1) an out-
let survey gathering information on availability; 2) a
household survey in the same geographical areas assessing
treatment-seeking behaviour, usage and purchase price
and 3) a supply chain mapping including an analysis of
mark-up at each level. All components are conducted as
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Figure 2 Research Methods to Study Supply and Demand.
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demand side data as well as to allow for triangulation of
the results.
The indicators used for each study component were
developed in consultation with partners and the Advi-
sory Committee and are, as far as possible, consistent
with those proposed for the independent evaluation of
AMFm [12], Demographic and Health Surveys [13] and
Malaria Indicators Surveys [14]. Table 1 illustrates the
project’s key indicators.
The outlet survey
The outlet survey studies both the public and private sec-
tors in order to have a complete picture of the anti-malar-
ial market within a country at the retail level. The survey
is conducted approximately three times over the life of the
project in each country to measure trends over time.
A cross-sectional survey is conducted of outlets with
the potential to stock and dispense anti-malarials to
patients/caregivers. Building on previous outlet survey
methodologies [15-17], the outlet survey measures price,
availability and volumes of anti-malarial medicines and
the price and availability RDTs. The sample is based on a
one-staged cluster design using probability proportion to
population size, that provides nationally representative
data sufficiently powered to allow for comparisons over
time, between the public and private sectors and across
sub-populations where stratified. The sampling strategy
was designed to detect a 20 percentage point change in
the primary outcome measure, availability of ACT. The
cluster selected was an administrative unit with on aver-
age 10, 000 to 15, 000 inhabitants, such as a sub-district
or parish.
Stratification was determined by consulting with the
Ministry of Health (MOH) in each country to identify
characteristics of sub-populations that are relevant for
policy consideration. Table 2 provides an overview of
country stratification, which varies across countries by
number and characteristics.
In order to capture the market as a whole rather than
some of its segments, all outlet types with the potential
to dispense anti-malarials were included and a census of
these within each selected cluster was conducted. Outlets
with this potential were identified at a country level
through consultation with local stakeholders. The types
of outlets vary somewhat from country to country, and
are classified as falling either within the Public/Not-for-
Profit Sector or the Private Sector categories. The Public/
Not-for-Profit sector consists of public health facilities,
community health workers and not-for-profit health
Table 1 Selected Project Indicators
Category Indicator description
Availability Proportion of outlets that:
￿ Have in stock: any anti-malarial, specified anti-malarial categories
￿ Reported no disruption in stock of anti-malarials in the last three months
￿ Have either rapid diagnostic tests or microscopic blood testing facilities
Price ￿ Median price of a full adult course by anti-malarial category
￿ Household price of fever episode treated with an anti-malarial
Market Share ￿ Total volume of an anti-malarial category sold or distributed in the last week as a proportion of the total
volume of all anti-malarials sold or distributed in the last week
Provider/wholesaler knowledge and
behaviour
Proportion of providers that:
￿ Correctly state: the recommended first line treatment, the correct dosing regimen
￿ Can list at least one danger sign in a child that requires referral to a public health facility
Use Proportion of children under five with fever in the past 2 weeks that:
￿ Received anti-malarial treatment, by anti-malarial category, and source, the same or next of fever onset, by
socio-economic quintile
￿ Received a blood test for malaria the same or next day of fever onset
Caregiver knowledge and behaviour Proportion of Caregivers that:
￿ Sought treatment for fever, by source, and reason(s) for this choice(s)
￿ Can name the first-line drug. Know a common brand of first-line ACT.
￿ Request a specific anti-malarial by category or brand name from providers.
￿ Express their opinion on the most effective malaria treatment for adults, by anti-malarial category
Supply chain structure ￿ Minimum and maximum number of steps in the distribution chain
￿ Proportion of wholesalers that engage in specified business practices
￿ Proportion of wholesalers that have specific categories of anti-malarials and RDTs in stock
￿ Median percent and absolute mark-up applied by wholesalers, and retailers, by anti-malarial category
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The Private Sector is made up of private health facilities
and pharmaceutical outlets authorized to sell prescription
medicines, and a diverse range of other providers with
fewer or no health qualifications, such as drugs stores,
grocery stores, street hawkers and kiosks.
All anti-malarials found within an outlet are captured
in the survey. This means that drugs are captured
regardless of whether they are registered in the country
or recommended by the WHO. Given the large numbers
of different anti-malarials available on the market, anti-
malarials captured through the surveys are classified
into policy relevant categories when presenting results.
The classification of anti-malarials for analysis is shown
in Figure 3 along with a description of standard unit
employed, the adult equivalent treatment dose (AETD)
in Figure 4. Outlet Survey methods and results are pre-
sented in full in O’Connell et al (submitted).
The household survey
The objective of the household survey component is to
monitor consumer treatment-seeking behaviour for fever.
It is a population based, cross-sectional survey that takes
place twice over the length of the project, at baseline and
end-line, either at the same time or soon after the collec-
tion of outlet survey data. It takes place in the same geo-
graphical areas as the outlet survey and allows for
comparisons over time and across strata, where relevant.
It is powered to detect a 20 percentage point difference
in the key outcome indicator “the proportion of children
under five with fever in the past two weeks who used any
anti-malarial the same or next day of the onset of fever”.
The study mirrors methods used in typical population
based surveys and follows standard Demographic and
Health Survey sampling procedures. A household is eligi-
ble if there is a child under 5 with a history of fever in the
past two weeks, except in Cambodia, where eligibility is
based on any family member with fever in the past two
weeks due to low malaria prevalence rates. The question-
naire captures information on the type of anti-malarial
treatments taken (if any), the price paid for treatment and
related fees, treatment sources, distance travelled to obtain
treatment, knowledge related to malaria, any diagnostic
test received and price of diagnosis. An additional module
was also administered to adults in an attempt to ascertain
types of anti-malarial treatment taken for fever, source
and price, which could be matched with supply side
results. Formative research was conducted at the country
level in order to identify potential determinants of appro-
priate treatment behaviour. T h e s ew e r es u b s e q u e n t l y
included in the main survey as multi-item scales aimed at
capturing attitudes and perceptions of respondents, which
assist with identifying information on determinants
needed for demand creation activities. Household Survey
Table 2 Country Stratification
Country # of
Strata
Strata Description
Benin 1 None
Cambodia 2 1. Areas where P. falciparum parasite resistance to artemisinin is documented ("Containment Zone 1”)o r
where resistance is feared to have spread but not formally detected ("Containment Zone 2”)
2. Other Areas of the country
Source: Cambodia National Malaria (CNM) Programme, Kingdom of Cambodia
Democratic Republic of
Congo (DRC)
4 1. North-East Provinces: Oriental, Nord Kivu, Sud Kivu, and Maniema
2. North West Provinces: Bas-Congo, Bandundu, and Equateur
3. Centre-South Provinces: Katanga, Kasai Oriental, and Kasai Occidental
4. Capital city: Kinshasa
Source: Localized censuses in health zones conducted between 2001 and 2004, with the support of various INGOS
Madagascar 2 1. Urban areas
2. Rural areas
Source: Cartographie censitaire de la population 2009. Institut National de Statistique.
Nigeria 6 1. North-Central states: Benue, Abuja-FCT, Kogi, Kwara, Nasarawa, Niger, Plateau
2. North East states: Adamawa, Bauchi, Borno, Gombe, Taraba, Yobe
3. North West states: Jigawa, Kaduna, Kano, Katsina, kebbi, Sokoto, Zamfara
4. South East states: Abia, Anambra, Ebonyi, Enugu, Imo
3. South South states: Akwa ibom, Bayelsa, Cross rivers, Delta, Edo, Rivers
4. South West states: Ekiti, Lagos, Ogun, Ondo, Osun, Oyo
Source: Nigeria National Population Commission
Uganda 2 1. Low malaria transmission areas
2. Medium to high malaria transmission areas
Source: Malaria Control Programme, Ministry of Health, Uganda
Zambia 2 1. Urban areas
2. Rural areas
Source: Zambia Population Census Frame, 2000. Central Statistical Office, Lusaka, Zambia
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(submitted).
The supply chain study
The supply chain component employs quantitative and
qualitative methods to study the distribution chain for
anti-malarial drugs from factory gate/port of entry to
consumer, mark-ups along the supply chain, market struc-
ture including level and forms of competition, and the pol-
icy/regulatory environment. The objective is to provide
policy makers with a map of the supply chain for anti-
malarials and RDTs, including evidence on wholesaler
volumes and the components of the consumer price in the
context of the current market and policy influences on the
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Figure 3 Presenting results: Classifying anti-malarial drugs.
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ǁĂƐƐĐĂůĞĚƚŽƚŚĞĞƋƵŝǀĂůĞŶƚŶƵŵďĞƌŽĨĨƵůůĐŽƵƌƐĞƐƐŽůĚŝŶƚŚĞƉƌĞǀŝŽƵƐǁĞĞŬ͘&ŽƌĐŽŵďŝŶĂƚŝŽŶĂŶƚŝͲŵĂůĂƌŝĂůƐ͕ŽŶĞĚƌƵŐŝŶ
ƚŚĞĐŽŵďŝŶĂƚŝŽŶǁĂƐƐĞůĞĐƚĞĚĨŽƌƚŚĞƐĞĐĂůĐƵůĂƚŝŽŶƐ;Ğ͘Ő͘ƚŚĞĂƌƚĞƐƵŶĂƚĞĐŽŵƉŽŶĞŶƚŽĨĂƌƚĞƐƵŶĂƚĞͲĂŵŽĚŝĂƋƵŝŶĞͿ͘
ŶƚŝͲŵĂůĂƌŝĂůĚƌƵŐƐŵĂŝŶůǇŝŶƚĞŶĚĞĚĨŽƌƉƌŽƉŚǇůĂǆŝƐĂŶĚĚƌƵŐĐŽŵďŝŶĂƚŝŽŶƐŶŽƚƵƐĞĚƚŽƚƌĞĂƚŵĂůĂƌŝĂďƵƚƚŚĂƚĐŽŶƚĂŝŶĂŶ
ŝŶŐƌĞĚŝĞŶƚǁŝƚŚĂŶƚŝͲŵĂůĂƌŝĂůĂĐƚŝŽŶĂƌĞĞǆĐůƵĚĞĚĨƌŽŵĂŶĂůǇƐŝƐ͖ŚŽǁĞǀĞƌ͕ŝŶƚŚĞĐĂƐĞ ŽĨĂŵĂůĂƌŝĂƉƌŽƉŚǇůĂǆŝƐǁŚŝĐŚĐŽƵůĚ
ďĞƵƐĞĚĨŽƌƚƌĞĂƚŵĞŶƚŝŶƚŚĞĂďƐĞŶĐĞŽĨĂůůŽƚŚĞƌƚǇƉŝĐĂůĂŶƚŝͲŵĂůĂƌŝĂůƐ͕ƚŚĞƐĞƉƌŽĚƵĐƚƐǁĞƌĞŝŶĐůƵĚĞĚŝŶŵĞĂƐƵƌĞƐŽĨĂŶƚŝͲ
ŵĂůĂƌŝĂůĂǀĂŝůĂďŝůŝƚǇ͘
Figure 4 Presenting results: Employing standard units.
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survey of wholesalers of anti-malarials and qualitative in-
depth interviews throughout the distribution chain.
We conduct a cross-sectional survey amongst wholesa-
lers that operate in the private commercial distribution
chain that serves the public and private sector. Respon-
dents are identified through a bottom-up approach during
which wholesalers are identified by their customers until
the top of the chain is reached. The survey collects data
on the supply chain structure, wholesaler characteristics
and business practices, wholesale outlet licensing and
inspection, wholesaler knowledge, qualifications and train-
ing, and availability, purchase price and mark-ups for anti-
malarials and RDTs.
A sub-set of retailers and wholesalers in the distribution
chain undergoes in-depth interviews which collect data on
questions that are not readily addressed using quantitative
methods. This includes complex issues such as horizontal
and vertical integration of the market; subjective percep-
tions and opinions of staff; and the exploration of sensitive
commercial and regulatory issues.
Supply chain research methods are presented in full in
“Supply Chain Survey Results, Cambodia, January 2011”
[18].
Dissemination
An additional objective of ACTwatch is to ensure that
policy makers at both the national and international level
have access to our findings through dissemination. At the
national level, we organize workshops targeting key sta-
keholders such as donors, government, and NGOs. The
workshop serves as an opportunity for country-level sta-
keholders to interpret and discuss results in the context
of their operating environment. Baseline results discussed
by O’Connell et al (submitted) and Littrell et al (sub-
mitted)have been presented to stakeholders in ACT-
Watch countries. Dissemination at the international level
is conducted at scientific conferences (MIM 2009,
ASTMH, IHEA) and meetings targeting policy makers
including donors, such as PMI and the Global Fund, and
international organizations. The advisory committee has
helped shape the presentation of results, particularly
multi-country comparisons, in order to convey their rele-
vance. Country-specific results as well as study designs
and tools are available online [19].
Discussion
The past decade has seen important investments to
increase access to quality-assured ACT. However, policy
makers have had limited evidence on which to draw in
selecting among different delivery channels. On the supply
side, research has tended to focus on the public sector’s
health facilities and supply chain rather than the market as
a whole, with some limited exceptions [20,21]. On the
demand side, large-scale surveys including DHS, MICS
and MIS, have generally been conducted and interpreted
in the absence of an understanding of the overall market.
The ACTwatch research project presents an opportunity
to provide policy-makers with results on both the demand
and supply side determinants of anti-malarial access.
There are four key features of this project. First is overlap
of the outlet, household and supply chain components
where nationally representative data are collected over
similar periods and using a common sampling approach.
This allows for a better understanding of how variables
such as availability and price collected through the outlet
survey may affect the treatment decisions collected during
the household survey; or how mark-ups at different levels
of the supply chain affect final retail prices and household
costs. A second feature is the number and diversity of
countries that are captured using comparable methods,
including standardized tools, intensive training of field
staff, rigorous monitoring procedures and centralized ana-
lysis. The approach allows for results to be compared
across countries and should fuel the international policy
debate. It is anticipated that policy-makers will be as inter-
ested in common themes that run across countries as they
will of real differences between countries. Another distin-
guishing feature of this research is its ability to measure
trends in nationally representative data over time. A final
feature is the project’s aim to disseminate findings widely
so that policy-makers may use these for decision-making
in specific areas such as drug regulation, supply chain
management and training packages as well as for higher
level policies such as the role of the private sector in the
anti-malarial market.
These strengths make the research design well adapted
to monitor the impact of the AMFm pilot on drug prices,
market share, availability and use. Four of the eight
AMFm phase 1 pilot countries are included in the ACT-
watch project: Madagascar, Nigeria, Uganda and Cambo-
dia, and the indicators that we collect overlap with those
being employed by an independent evaluation commis-
sioned as part of the AMFm’s Monitoring & Evaluation
Technical Framework. Our outlet survey methodologies,
tools and results have fed into the study design developed
by the Independent Evaluator and relevant country outlet
survey results collected by ACTwatch will form part of the
evaluation’s baseline and endline data. In addition, early
ACTwatch supply chain data and outlet survey results
were employed in designing AMFm country proposals
suggesting that our results could be useful for planning
other implementation strategies. It is also likely that com-
parisons between the results of AMFm and non-AMFm
countries captured in our research will be made.
Despite its strengths, the research methodology has
several limitations. First, given the observational study
design, it may be difficult to identify the influence of
Shewchuk et al. Malaria Journal 2011, 10:325
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Page 7 of 9individual factors on trends observed over time, as many
factors such as changes in donor funding, regulation and
other interventions may simultaneously affect our key
outcomes in a given period. Second, given the cross-sec-
tional nature of the surveys, data are only collected over
a relatively short time period and do not capture seasonal
and other fluctuations in supply and demand. However,
as the outlet and household surveys are conducted at a
national level during malaria transmission periods, the
data can be considered to provide an accurate picture of
the situation during key seasons for malaria treatment.
Third, data collected are respondent-dependent and the
respondent could withhold or misrepresent some infor-
mation. On the supply side in particular, providers and
wholesalers may prefer not to provide accurate informa-
tion on sensitive topics such as mark-ups or stocking
rates of substandard products, particularly in countries
where there is a strong regulatory structure. That said,
certain data such as types of drugs and price can be trian-
gulated between wholesaler, outlet and household levels
to check accuracy of findings.
Another challenge is related to ensuring that the
research has country-specific relevance without compro-
mising the ability to compare across countries. Although
standardized, the methodology is sufficiently supple to
capture sub-population stratification requirements with
adequate power, and differences in market structure and
outlet types for each country. The challenge that this
adaptability has posed is in determining how far changes
can be made without jeopardizing comparability of results
and has meant that the research is not always as country-
relevant as local stakeholders would like. This is an intrin-
sic problem to multi-country studies, which in this case is
heightened by the diversity of the selected study countries.
A key question is whether it is feasible to continue to
research anti-malarial markets on such a large scale on
an on-going basis. One option would be to use existing
national household surveys such as the DHS to provide
information on the use of anti-malarials. One of the
drawbacks to such an approach is a risk that temporal
proximity across study components could be lost as
timelines would no longer be within the control of this
research project. It is also possible that these existing
surveys may not be in position to collect a sufficient
level of detail. There are no other sources of standar-
dized supply side data (outlet or supply chain).
Conclusion
ACTwatch is a unique multi-country research project
that sheds light on the complicated and often unregu-
lated anti-malarial market by threading together anti-
malarial supply and consumer behaviour. It provides
countries with essential information necessary to define
interventions to increase access to recommended
quality-assured ACT and RDTs. In addition, because of
its ability to detect change over time, it is well suited to
monitor the effects of donor investments and novel
mechanisms like the AMFm.
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